1
|
Frey B, Holzinger D, Taylor K, Ehrnhoefer DE, Striebinger A, Biesinger S, Gasparini L, O'Neill MJ, Wegner F, Barghorn S, Höglinger GU, Heym RG. Tau seed amplification assay reveals relationship between seeding and pathological forms of tau in Alzheimer's disease brain. Acta Neuropathol Commun 2023; 11:181. [PMID: 37964332 PMCID: PMC10644662 DOI: 10.1186/s40478-023-01676-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 10/23/2023] [Indexed: 11/16/2023] Open
Abstract
Tau seed amplification assays (SAAs) directly measure the seeding activity of tau and would therefore be ideal biomarkers for clinical trials targeting seeding-competent tau in Alzheimer's disease (AD). However, the precise relationship between tau seeding measured by SAA and the levels of pathological forms of tau in the AD brain remains unknown. We developed a new tau SAA based on full-length 0N3R tau with sensitivity in the low fg/ml range and used it to characterize 103 brain samples from three independent cohorts. Tau seeding clearly discriminated between AD and control brain samples. Interestingly, seeding was absent in Progressive Supranuclear Palsy (PSP) putamen, suggesting that our tau SAA did not amplify 4R tau aggregates from PSP brain. The specificity of our tau SAA for AD brain was further supported by analysis of matched hippocampus and cerebellum samples. While seeding was detected in hippocampus from Braak stages I-II, no seeding was present in AD cerebellum that is devoid of tau inclusions. Analysis of 40 middle frontal gyrus samples encompassing all Braak stages showed that tau SAA seeding activity gradually increased with Braak stage. This relationship between seeding activity and the presence of tau inclusions in AD brain was further supported by robust correlations between tau SAA results and the levels of phosphorylated tau212/214, phosphorylated tau181, aggregated tau, and sarkosyl-insoluble tau. Strikingly, we detected tau seeding in the middle frontal gyrus already at Braak stage II-III, suggesting that tau SAA can detect tau pathology earlier than conventional immunohistochemical staining. In conclusion, our data suggest a quantitative relationship between tau seeding activity and pathological forms of tau in the human brain and provides an important basis for further development of tau SAA for accessible human samples.
Collapse
Affiliation(s)
- Bryan Frey
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
- Department of Neurology, Hannover Medical School, Hanover, Germany.
- Center for Systems Neuroscience, Hannover, Germany.
| | - David Holzinger
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Keenan Taylor
- AbbVie Bioresearch Center, Biotherapeutics and Genetic Medicine Technologies, Worcester, MA, USA
| | - Dagmar E Ehrnhoefer
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Andreas Striebinger
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Sandra Biesinger
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Laura Gasparini
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Michael J O'Neill
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Florian Wegner
- Department of Neurology, Hannover Medical School, Hanover, Germany
- Center for Systems Neuroscience, Hannover, Germany
| | - Stefan Barghorn
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Günter U Höglinger
- Department of Neurology, Hannover Medical School, Hanover, Germany
- Center for Systems Neuroscience, Hannover, Germany
- German Center for Neurodegenerative Diseases E.V. (DZNE), Munich, Germany
- Department of Neurology, LMU University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany
| | - Roland G Heym
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Research, Knollstrasse, 67061, Ludwigshafen, Germany.
| |
Collapse
|
2
|
Limorenko G, Tatli M, Kolla R, Nazarov S, Weil MT, Schöndorf DC, Geist D, Reinhardt P, Ehrnhoefer DE, Stahlberg H, Gasparini L, Lashuel HA. Fully co-factor-free ClearTau platform produces seeding-competent Tau fibrils for reconstructing pathological Tau aggregates. Nat Commun 2023; 14:3939. [PMID: 37402718 PMCID: PMC10319797 DOI: 10.1038/s41467-023-39314-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Accepted: 06/06/2023] [Indexed: 07/06/2023] Open
Abstract
Tau protein fibrillization is implicated in the pathogenesis of several neurodegenerative diseases collectively known as Tauopathies. For decades, investigating Tau fibrillization in vitro has required the addition of polyanions or other co-factors to induce its misfolding and aggregation, with heparin being the most commonly used. However, heparin-induced Tau fibrils exhibit high morphological heterogeneity and a striking structural divergence from Tau fibrils isolated from Tauopathies patients' brains at ultra- and macro-structural levels. To address these limitations, we developed a quick, cheap, and effective method for producing completely co-factor-free fibrils from all full-length Tau isoforms and mixtures thereof. We show that Tau fibrils generated using this ClearTau method - ClearTau fibrils - exhibit amyloid-like features, possess seeding activity in biosensor cells and hiPSC-derived neurons, retain RNA-binding capacity, and have morphological properties and structures more reminiscent of the properties of the brain-derived Tau fibrils. We present the proof-of-concept implementation of the ClearTau platform for screening Tau aggregation-modifying compounds. We demonstrate that these advances open opportunities to investigate the pathophysiology of disease-relevant Tau aggregates and will facilitate the development of Tau pathology-targeting and modifying therapies and PET tracers that can distinguish between different Tauopathies.
Collapse
Affiliation(s)
- Galina Limorenko
- Laboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland
| | - Meltem Tatli
- Laboratory of Biological Electron Microscopy, Institute of Physics, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland
| | - Rajasekhar Kolla
- Laboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland
| | - Sergey Nazarov
- Biological Electron Microscopy Facility, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland
| | - Marie-Theres Weil
- Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061, Ludwigshafen, Germany
| | - David C Schöndorf
- Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Daniela Geist
- Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Peter Reinhardt
- Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Dagmar E Ehrnhoefer
- Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Henning Stahlberg
- Laboratory of Biological Electron Microscopy, Institute of Physics, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland
- Department of Fund. Microbiology, Faculty of Biology and Medicine, University of Lausanne, CH-1015, Lausanne, Switzerland
| | - Laura Gasparini
- Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061, Ludwigshafen, Germany
| | - Hilal A Lashuel
- Laboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland.
| |
Collapse
|
3
|
Reinhardt L, Musacchio F, Bichmann M, Behrendt A, Ercan-Herbst E, Stein J, Becher I, Haberkant P, Mader J, Schöndorf DC, Schmitt M, Korffmann J, Reinhardt P, Pohl C, Savitski M, Klein C, Gasparini L, Fuhrmann M, Ehrnhoefer DE. Dual truncation of tau by caspase-2 accelerates its CHIP-mediated degradation. Neurobiol Dis 2023; 182:106126. [PMID: 37086756 DOI: 10.1016/j.nbd.2023.106126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 03/30/2023] [Accepted: 04/12/2023] [Indexed: 04/24/2023] Open
Abstract
Intraneuronal aggregates of the microtubule binding protein Tau are a hallmark of different neurodegenerative diseases including Alzheimer's disease (AD). In these aggregates, Tau is modified by posttranslational modifications such as phosphorylation as well as by proteolytic cleavage. Here we identify a novel Tau cleavage site at aspartate 65 (D65) that is specific for caspase-2. In addition, we show that the previously described cleavage site at D421 is also efficiently processed by caspase-2, and both sites are cleaved in human brain samples. Caspase-2-generated Tau fragments show increased aggregation potential in vitro, but do not accumulate in vivo after AAV-mediated overexpression in mouse hippocampus. Interestingly, we observe that steady-state protein levels of caspase-2 generated Tau fragments are low in our in vivo model despite strong RNA expression, suggesting efficient clearance. Consistent with this hypothesis, we find that caspase-2 cleavage significantly improves the recognition of Tau by the ubiquitin E3 ligase CHIP, leading to increased ubiquitination and faster degradation of Tau fragments. Taken together our data thus suggest that CHIP-induced ubiquitination is of particular importance for the clearance of caspase-2 generated Tau fragments in vitro and in vivo.
Collapse
Affiliation(s)
- Lydia Reinhardt
- BioMed X Institute, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany; AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Fabrizio Musacchio
- Neuroimmunology and Imaging Group, German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Building 99, 53127 Bonn, Germany
| | - Maria Bichmann
- BioMed X Institute, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany
| | - Annika Behrendt
- BioMed X Institute, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany
| | - Ebru Ercan-Herbst
- BioMed X Institute, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany
| | - Juliane Stein
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Isabelle Becher
- European Molecular Biology Laboratory (EMBL), Meyerhofstraße 1, 69117 Heidelberg, Germany
| | - Per Haberkant
- European Molecular Biology Laboratory (EMBL), Meyerhofstraße 1, 69117 Heidelberg, Germany
| | - Julia Mader
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - David C Schöndorf
- BioMed X Institute, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany; AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Melanie Schmitt
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Jürgen Korffmann
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Peter Reinhardt
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Christian Pohl
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Mikhail Savitski
- European Molecular Biology Laboratory (EMBL), Meyerhofstraße 1, 69117 Heidelberg, Germany
| | - Corinna Klein
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Laura Gasparini
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany
| | - Martin Fuhrmann
- Neuroimmunology and Imaging Group, German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Building 99, 53127 Bonn, Germany
| | - Dagmar E Ehrnhoefer
- BioMed X Institute, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany; AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
| |
Collapse
|
4
|
Kulkarni AS, Ideozu J, Vasanthakumar A, Ammar A, Murphy E, Asque E, Plaas C, Klein C, Ried JS, Barghorn S, Gasparini L. Multi‐tissue profiling of RNA and DNA‐methylation signatures of progressive tau neuropathology in tau transgenic mice. Alzheimers Dement 2022. [DOI: 10.1002/alz.060736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Corinna Klein
- AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany
| | - Janina S Ried
- AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany
| | | | | |
Collapse
|
5
|
Giani A, Franconi A, Nicolussi Paolaz S, Zampieri A, Falceri A, Gasparini L, Mattachini E, Santuz B, Zamboni M, Fantin F. P247 ARTERIAL STIFFNESS, SUBENDOCARDIAL PERFUSION AND 30–DAYS READMISSION IN ELDERLY INDIVIDUALS WITH HEART FAILURE. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Arterial stiffness and subendocardial perfusion impairment significantly affect cardiovascular morbidity and mortality, playing a relevant role in heart failure. The aim of the present study was to describe the trend of hemodynamical parameters, arterial stiffness indexes and subendocardial viability ratio (SEVR) in geriatric patients, hospitalized with hearth failure, and to define the main predictors of 30–days readmission. A cohort of 41 patients, admitted to the Geriatric ward of Verona University Hospital, affected by heart failure, was included in the study. Each subject underwent clinical evaluation, geriatric comprehensive assessment, routine laboratory testing, and cardiac ultrasound. At the time of admission, after achievement of clinical stability (defined as switching from intravenous to oral diuretic therapy) and at the time of discharge, blood pressure measurement and applanation arterial tonometry (with evaluation of carotid–femoral pulse wave velocity –PWVcf– and SEVR) were also performed. SEVR was corrected for hemoglobin concentration and oxygen saturation. Through the three evaluations, a progressive decrease in PWVcf was described (17.79±4.49 m/s, 13.54±4.54 m/s, 9.94±3.73 m/s respectively, p < 0.001); the trend remained significant even after adjustment for age, gender, mean arterial pressure (MAP) variation and left ventricular ejection fraction (LVEF) (p < 0.001). A significant improvement was registered for both SEVR (83.48±24.43, 97.94±26.84, 113.29±38.02 respectively) and corrected SEVR (12.74±4.69, 15.71±5.30, 18.55±6.66 respectively) values (p < 0.001 for both), and it was still significant when adjusted for age, gender, MAP variation and LVEF (p < 0.001). After discharge, 26.8% of patients was readmitted within 30 days. In a multivariate binary logistic regression analysis, considering 30–days readmission as dependent variable, PWVcf at discharge was the only predictor of readmission (OR 2.004, CI 1.154–3.481, p = 0.014) In conclusion, medical therapy seems to improve arterial stiffness and subendocardial perfusion in geriatric patients hospitalized with hearth failure. Furthermore, PWVcf is a valid predictor of 30–days readmission. Its feasibility and reproducibility in clinical practice, may provide an instrument to detect heart failure patients at high risk of rehospitalization.
Collapse
Affiliation(s)
- A Giani
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - A Franconi
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - S Nicolussi Paolaz
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - A Zampieri
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - A Falceri
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - L Gasparini
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - E Mattachini
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - B Santuz
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - M Zamboni
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| | - F Fantin
- AOUI VERONA – GERIATRIA B – SCUOLA DI SPECIALIZZAZIONE IN GERIATRIA – UNIVERSITÀ DI VERONA, VERONA
| |
Collapse
|
6
|
Gasparini L, Di Guglielmo F, Borgia M, Nuzzo M, Ursini L, Di Pilla A, Caravatta L, Genovesi D. PO-1455 Oncogeriatric assessment in elderly breast cancer patients: a monoistitutional experience. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03419-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Caravatta L, Gasparini L, Taraborrelli M, Borgia M, Candeloro M, Bottone I, Porreca E, Genovesi D. PO-1456 Predictive toxicity markers in elderly patients underwent RT and managed by an oncogeriatric model. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03420-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Gasparini L, Caravatta L, Taraborrelli M, Borgia M, Genovesi D. PO-1049 COVID-19 pandemic impact on psychological state and care of cancer patients undergoing radiotherapy. Radiother Oncol 2022. [PMCID: PMC9153884 DOI: 10.1016/s0167-8140(22)03013-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Gasparini L, Borgia M, Trignani M, Di Pilla A, Porreca A, Di Nicola M, Genovesi D. PO-1073 NLR and PLR ratio as predictive markers of outcomes in head and neck squamous cell carcinoma. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03037-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Barini E, Plotzky G, Mordashova Y, Hoppe J, Rodriguez-Correa E, Julier S, LePrieult F, Mairhofer I, Mezler M, Biesinger S, Cik M, Meinhardt MW, Ercan-Herbst E, Ehrnhoefer DE, Striebinger A, Bodie K, Klein C, Gasparini L, Schlegel K. Tau in the brain interstitial fluid is fragmented and seeding-competent. Neurobiol Aging 2021; 109:64-77. [PMID: 34655982 DOI: 10.1016/j.neurobiolaging.2021.09.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 09/02/2021] [Accepted: 09/08/2021] [Indexed: 11/19/2022]
Abstract
In Alzheimer disease, Tau pathology is thought to propagate from cell to cell throughout interconnected brain areas. However, the forms of Tau released into the brain interstitial fluid (ISF) in vivo during the development of Tauopathy and their pathological relevance remain unclear. Combining in vivo microdialysis and biochemical analysis, we find that in Tau transgenic mice, human Tau (hTau) present in brain ISF is truncated and comprises at least 10 distinct fragments spanning the entire Tau protein. The fragmentation pattern is similar across different Tau transgenic models, pathological stages and brain areas. ISF hTau concentration decreases during Tauopathy progression, while its phosphorylation increases. ISF from mice with established Tauopathy induces Tau aggregation in HEK293-Tau biosensor cells. Notably, immunodepletion of ISF phosphorylated Tau, but not Tau fragments, significantly reduces its ability to seed Tau aggregation and only a fraction of Tau, separated by ultracentrifugation, is seeding-competent. These results indicate that ISF seeding competence is driven by a small subset of Tau, which potentially contribute to the propagation of Tau pathology.
Collapse
Affiliation(s)
- Erica Barini
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany.
| | - Gudrun Plotzky
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Yulia Mordashova
- AbbVie Deutschland GmbH & Co. KG, Discovery and Exploratory Statistics (DIVES), Knollstrasse, Ludwigshafen, Germany
| | - Jonas Hoppe
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Esther Rodriguez-Correa
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Sonja Julier
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Florie LePrieult
- AbbVie Deutschland GmbH & Co. KG, Drug Metabolism and Pharmacokinetics, Knollstrasse, Ludwigshafen, Germany
| | - Ina Mairhofer
- AbbVie Deutschland GmbH & Co. KG, Drug Metabolism and Pharmacokinetics, Knollstrasse, Ludwigshafen, Germany
| | - Mario Mezler
- AbbVie Deutschland GmbH & Co. KG, Drug Metabolism and Pharmacokinetics, Knollstrasse, Ludwigshafen, Germany
| | - Sandra Biesinger
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Miroslav Cik
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Marcus W Meinhardt
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | | | - Dagmar E Ehrnhoefer
- BioMed X GmbH, Im Neuenheimer Feld, Heidelberg, Germany; AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Andreas Striebinger
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Karen Bodie
- AbbVie Deutschland GmbH & Co. KG, Preclinical Safety, Knollstrasse, Ludwigshafen, Germany
| | - Corinna Klein
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany
| | - Laura Gasparini
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany.
| | - Kerstin Schlegel
- AbbVie Deutschland GmbH & Co. KG , Neuroscience Discovery, Knollstrasse, Ludwigshafen, Germany.
| |
Collapse
|
11
|
Gasparini L, Gasparini L, Ursini L, Nuzzo M, Di Tommaso M, Di Guglielmo F, Borgia M, Genovesi D, Caravatta L. PO-1136 Radiotherapy for breast cancer in women with autoimmune rheumatologic diseases. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07587-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Rosa C, Di Guglielmo F, Gasparini L, Caravatta L, Di Tommaso M, Pieragostino D, Del Boccio P, Cicalini I, Genovesi D. OC-0402 Metabolomics as predictor of treatment response in neoadjuvant chemoradiation for rectal cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06889-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Gasparini L, Caravatta L, Taraborrelli M, Allega F, Candeloro M, Bottone I, Porreca E, Genovesi D. PH-0332 The role of multidimensional evaluation in curative radiotherapy for elderly patients (aged ≥75). Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07305-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Marcucci S, Caravatta L, Rosa C, Nuzzo M, Di Tommaso M, Taraborrelli M, Di Carlo C, Di Guglielmo F, Gasparini L, Adorante N, Genovesi D. PO-1970 4D-CBCT (Symmetry Elekta X-ray) for ITV generation in thoracic stereotactic radiotherapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08421-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Rosa C, Di Guglielmo F, Gasparini L, Caravatta L, Di Tommaso M, Martino G, Castaldi P, Genovesi D. PD-0838 Rectal cancer volume delineation between morphological and functional images: CT, T2/DWIMRI, PET-CT. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07117-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Bichmann M, Prat Oriol N, Ercan-Herbst E, Schöndorf DC, Gomez Ramos B, Schwärzler V, Neu M, Schlüter A, Wang X, Jin L, Hu C, Tian Y, Ried JS, Haberkant P, Gasparini L, Ehrnhoefer DE. SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer's disease. Mol Neurodegener 2021; 16:46. [PMID: 34215303 PMCID: PMC8254302 DOI: 10.1186/s13024-021-00468-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 06/18/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. METHODS We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. RESULTS Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. CONCLUSIONS Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon.
Collapse
Affiliation(s)
- Maria Bichmann
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
| | - Nuria Prat Oriol
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
- Present address: Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, 08003, Barcelona, Spain
| | - Ebru Ercan-Herbst
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
| | - David C Schöndorf
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstr. 50, 67061, Ludwigshafen am Rhein, Germany
| | - Borja Gomez Ramos
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
- Present address: Life Sciences Research Unit, University of Luxembourg, L-4367, Belvaux, Luxembourg
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, L-4362, Esch-sur-Alzette, Luxembourg
| | - Vera Schwärzler
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
| | - Marie Neu
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstr. 50, 67061, Ludwigshafen am Rhein, Germany
| | - Annabelle Schlüter
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstr. 50, 67061, Ludwigshafen am Rhein, Germany
| | - Xue Wang
- AbbVie Bioresearch Center (ABC), 100 Research Dr, Worcester, MA, 01605, USA
| | - Liang Jin
- AbbVie Bioresearch Center (ABC), 100 Research Dr, Worcester, MA, 01605, USA
| | - Chenqi Hu
- AbbVie Bioresearch Center (ABC), 100 Research Dr, Worcester, MA, 01605, USA
| | - Yu Tian
- AbbVie Bioresearch Center (ABC), 100 Research Dr, Worcester, MA, 01605, USA
| | - Janina S Ried
- AbbVie Deutschland GmbH & Co. KG, Genomics Research Center, Knollstr. 50, 67061, Ludwigshafen am Rhein, Germany
| | - Per Haberkant
- European Molecular Biology Laboratory (EMBL), Meyerhofstraße 1, 69117, Heidelberg, Germany
| | - Laura Gasparini
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstr. 50, 67061, Ludwigshafen am Rhein, Germany
| | - Dagmar E Ehrnhoefer
- BioMed X Institute, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany.
- AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstr. 50, 67061, Ludwigshafen am Rhein, Germany.
| |
Collapse
|
17
|
Capua FD, Campajola M, Fiore D, Gasparini L, Sarnelli E, Aloisio A. Investigation of random telegraph signal in two junction layouts of proton irradiated CMOS SPADs. Sci Rep 2021; 11:8580. [PMID: 33883584 PMCID: PMC8060403 DOI: 10.1038/s41598-021-87962-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 03/22/2021] [Indexed: 11/16/2022] Open
Abstract
This paper focuses on the understanding of the Random Telegraph Signal (RTS) in Single-Photon Avalanche Diodes (SPAD). We studied the RTS of two different SPAD layouts, designed and implemented in a 150-nm CMOS process, after proton irradiation. The two structures are characterized by different junction types: the first structure is constituted by a P+/Nwell junction, while the second is formed by a Pwell/Niso junction. RTS occurrence has been measured in about one thousand SPAD pixels and the differences addressed in two layouts are motivated and discussed. Hypotheses on the RTS origin are drawn by analyzing the RTS time constants and the RTS occurrence evolution as a function of the annealing temperature.
Collapse
Affiliation(s)
- F Di Capua
- Department of Physics "E. Pancini", University of Naples Federico II, Naples, Italy. .,Istituto Nazionale di Fisica Nucleare, Naples, Italy.
| | - M Campajola
- Department of Physics "E. Pancini", University of Naples Federico II, Naples, Italy.,Istituto Nazionale di Fisica Nucleare, Naples, Italy
| | - D Fiore
- Center National d'Etudes Spatiales, Toulouse, France
| | - L Gasparini
- Fondazione Bruno Kessler (FBK), Integrated Radiation and Image Sensors Division, Trento, Italy
| | | | - A Aloisio
- Department of Physics "E. Pancini", University of Naples Federico II, Naples, Italy.,Istituto Nazionale di Fisica Nucleare, Naples, Italy
| |
Collapse
|
18
|
Tinarelli F, Ivanova E, Colombi I, Barini E, Balzani E, Garcia CG, Gasparini L, Chiappalone M, Kelsey G, Tucci V. Cell-cell coupling and DNA methylation abnormal phenotypes in the after-hours mice. Epigenetics Chromatin 2021; 14:1. [PMID: 33407878 PMCID: PMC7789812 DOI: 10.1186/s13072-020-00373-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Accepted: 11/13/2020] [Indexed: 11/10/2022] Open
Abstract
Background DNA methylation has emerged as an important epigenetic regulator of brain processes, including circadian rhythms. However, how DNA methylation intervenes between environmental signals, such as light entrainment, and the transcriptional and translational molecular mechanisms of the cellular clock is currently unknown. Here, we studied the after-hours mice, which have a point mutation in the Fbxl3 gene and a lengthened circadian period. Methods In this study, we used a combination of in vivo, ex vivo and in vitro approaches. We measured retinal responses in Afh animals and we have run reduced representation bisulphite sequencing (RRBS), pyrosequencing and gene expression analysis in a variety of brain tissues ex vivo. In vitro, we used primary neuronal cultures combined to micro electrode array (MEA) technology and gene expression. Results We observed functional impairments in mutant neuronal networks, and a reduction in the retinal responses to light-dependent stimuli. We detected abnormalities in the expression of photoreceptive melanopsin (OPN4). Furthermore, we identified alterations in the DNA methylation pathways throughout the retinohypothalamic tract terminals and links between the transcription factor Rev-Erbα and Fbxl3. Conclusions The results of this study, primarily represent a contribution towards an understanding of electrophysiological and molecular phenotypic responses to external stimuli in the Afh model. Moreover, as DNA methylation has recently emerged as a new regulator of neuronal networks with important consequences for circadian behaviour, we discuss the impact of the Afh mutation on the epigenetic landscape of circadian biology.
Collapse
Affiliation(s)
- Federico Tinarelli
- Genetics and Epigenetics of Behaviour (GEB) Laboratory, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.,BioMed X Innovation Center, Im Neuenheimer Feld 515, 69120, Heidelberg, Germany
| | - Elena Ivanova
- Epigenetics Programme, The Babraham Institute, Cambridge, UK
| | - Ilaria Colombi
- Neuroscience and Brain Technologies, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.,Brain Development and Disease, NBT, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy
| | - Erica Barini
- Neurodevelopmental and Neurodegenerative Disease Laboratory, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.,AbbVie Deutschland GmbH & Co, Knollstr, 67061, Ludwigshafen, Germany
| | - Edoardo Balzani
- Genetics and Epigenetics of Behaviour (GEB) Laboratory, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.,Center for Neural Science, New York University, New York, NY, 10006, USA
| | - Celina Garcia Garcia
- Genetics and Epigenetics of Behaviour (GEB) Laboratory, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy
| | - Laura Gasparini
- Neurodevelopmental and Neurodegenerative Disease Laboratory, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.,AbbVie Deutschland GmbH & Co, Knollstr, 67061, Ludwigshafen, Germany
| | - Michela Chiappalone
- Neuroscience and Brain Technologies, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.,Rehab Technologies, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy
| | - Gavin Kelsey
- Epigenetics Programme, The Babraham Institute, Cambridge, UK
| | - Valter Tucci
- Genetics and Epigenetics of Behaviour (GEB) Laboratory, Istituto Italiano Di Tecnologia, via Morego, 30, 16163, Genova, Italy.
| |
Collapse
|
19
|
Rosa C, Gasparini L, Di Guglielmo F, Delli Pizzi A, Seccia B, Cianci R, Basilico R, Augurio A, Ursini L, Porreca A, Di Nicola M, Caravatta L, Genovesi D. OC-0567: T2 and Apparent Diffusion Coefficient MRI for Cervical cancer delineation: agreement between volumes. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00589-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Schlegel K, Awwad K, Heym RG, Holzinger D, Doell A, Barghorn S, Jahn TR, Klein C, Mordashova Y, Schulz M, Gasparini L. N368-Tau fragments generated by legumain are detected only in trace amount in the insoluble Tau aggregates isolated from AD brain. Acta Neuropathol Commun 2019; 7:177. [PMID: 31722749 PMCID: PMC6854719 DOI: 10.1186/s40478-019-0831-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 10/17/2019] [Indexed: 01/20/2023] Open
Abstract
Intraneuronal insoluble inclusions made of Tau protein are neuropathological hallmarks of Alzheimer Disease (AD). Cleavage of Tau by legumain (LGMN) has been proposed to be crucial for aggregation of Tau into fibrils. However, it remains unclear if LGMN-cleaved Tau fragments accumulate in AD Tau inclusions.Using an in vitro enzymatic assay and non-targeted mass spectrometry, we identified four putative LGMN cleavage sites at Tau residues N167-, N255-, N296- and N368. Cleavage at N368 generates variously sized N368-Tau fragments that are aggregation prone in the Thioflavin T assay in vitro. N368-cleaved Tau is not detected in the brain of legumain knockout mice, indicating that LGMN is required for Tau cleavage in the mouse brain in vivo. Using a targeted mass spectrometry method in combination with tissue fractionation and biochemical analysis, we investigated whether N368-cleaved Tau is differentially produced and aggregated in brain of AD patients and control subjects. In brain soluble extracts, despite reduced uncleaved Tau in AD, levels of N368-cleaved Tau are comparable in AD and control hippocampus, suggesting that LGMN-mediated cleavage of Tau is not altered in AD. Consistently, levels of activated, cleaved LGMN are also similar in AD and control brain extracts. To assess the potential accumulation of N368-cleaved Tau in insoluble Tau aggregates, we analyzed sarkosyl-insoluble extracts from AD and control hippocampus. Both N368-cleaved Tau and uncleaved Tau were significantly increased in AD as a consequence of pathological Tau inclusions accumulation. However, the amount of N368-cleaved Tau represented only a very minor component (< 0.1%) of insoluble Tau.Our data indicate that LGMN physiologically cleaves Tau in the mouse and human brain generating N368-cleaved Tau fragments, which remain largely soluble and are present only in low proportion in Tau insoluble aggregates compared to uncleaved Tau. This suggests that LGMN-cleaved Tau has limited role in the progressive accumulation of Tau inclusions in AD.
Collapse
|
21
|
Rosa C, Gasparini L, Di Biase S, Di Carlo C, Allajbej A, Patani F, Fasciolo D, Vinciguerra A, Caravatta L, Genovesi D. EP-1460 Internal Margin evaluation in prone or supine rectal cancer patients using CBCT. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31880-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Gasparini L, Rosa C, Di Biase S, Di Carlo C, Allajbej A, Patani F, Fasciolo D, Porreca A, Di Nicola M, Caravatta L, Genovesi D. EP-1647 Neoadjuvant chemoradiotherapy in elderly rectal cancer patients in a mono-institutional experience. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32067-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Di Biase S, Patani F, Fasciolo D, Rosa C, Di Carlo C, Allajbej A, Gasparini L, Delli Pizzi A, Trignani M, Caravatta L, Genovesi D. EP-1238 Inter-observer variability in target delineation for brain metastases in stereotactic radiotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31658-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Allajbej A, Patani F, Di Biase S, Fasciolo D, Di Carlo C, Rosa C, Gasparini L, Di Francesco M, Falcone G, Quaternato G, Croce A, Di Pilla A, Trignani M, Caravatta L, Genovesi D. PO-0727 Voice outcome following radiotherapy or laser microsurgery in patients with early glottic cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31147-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
25
|
Altaibej A, Patani F, Di Biase S, Fasciolo D, Di Carlo C, Rosa C, Gasparini L, Di Francesco M, Falcone G, Quaternato G, Croce A, Di Pilla A, Trignani M, Genovesi D. PO-145 Voice outcome in patients with early glottic cancer following radiotherapy versus laser microsurgery. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30311-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Lo Martire V, Alvente S, Bastianini S, Berteotti C, Bombardi C, Calandra-Buonaura G, Capellari S, Cohen G, Cortelli P, Gasparini L, Padiath Q, Valli A, Zoccoli G, Silvani A. Mice overexpressing lamin B1 in oligodendrocytes recapitulate the age-dependent motor signs, but not the early autonomic cardiovascular dysfunction of autosomal-dominant leukodystrophy (ADLD). Exp Neurol 2018; 301:1-12. [PMID: 29262292 PMCID: PMC5809293 DOI: 10.1016/j.expneurol.2017.12.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 12/02/2017] [Accepted: 12/15/2017] [Indexed: 10/18/2022]
Abstract
Autosomal dominant leukodystrophy (ADLD) is a rare adult-onset demyelinating disease caused by overexpression of lamin B1, a nuclear lamina filament. Early autonomic dysfunction involving the cardiovascular system before progressive somatic motor dysfunction is a striking feature of most cases of ADLD. In the Plp-FLAG-LMNB1 transgenic mouse model, lamin B1 overexpression in oligodendrocytes elicits somatic motor dysfunction and neuropathology akin to ADLD. Here, we investigate whether Plp-FLAG-LMNB1 mice also develop autonomic cardiovascular dysfunction before or after somatic motor dysfunction. We find that Plp-FLAG-LMNB1 mice have preserved cardiovascular responses to changes in wake-sleep state and ambient temperature and normal indexes of autonomic modulation at 37-42weeks of age despite a progressive somatic motor dysfunction, which includes impairments of walking ability (the ability to walk on a narrow path was impaired in 80% of mice at 34-38weeks of age) and subtle breathing derangements. Only late in the development of the disease phenotype did Plp-FLAG-LMNB1 mice develop a structural deficit of sympathetic noradrenergic fibers, with a 38% decrease in fiber profiles in the kidneys at 44-47weeks of age. We demonstrate that while the Plp-FLAG-LMNB1 mouse model recapitulates the age-dependent motor dysfunction of ADLD, it does not show signs of early autonomic cardiovascular dysfunction, raising the possibility that oligodendrocyte dysfunction may not be sufficient to cause the full spectrum of clinical features present in ADLD.
Collapse
Affiliation(s)
- Viviana Lo Martire
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - Sara Alvente
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - Stefano Bastianini
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - Chiara Berteotti
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - Cristiano Bombardi
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - Giovanna Calandra-Buonaura
- Autonomic Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy; IRCCS, Institute of Neurological Sciences of Bologna, Bellaria University Hospital, Bologna, Italy
| | - Sabina Capellari
- Autonomic Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy; IRCCS, Institute of Neurological Sciences of Bologna, Bellaria University Hospital, Bologna, Italy
| | - Gary Cohen
- Sleep Investigation Laboratory, Centre for Sleep Health and Research, Royal North Shore Hospital, Sydney, Australia
| | - Pietro Cortelli
- Autonomic Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy; IRCCS, Institute of Neurological Sciences of Bologna, Bellaria University Hospital, Bologna, Italy
| | - Laura Gasparini
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT), Genova, Italy
| | - Quasar Padiath
- Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA
| | - Alice Valli
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - Giovanna Zoccoli
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
| | - Alessandro Silvani
- Laboratory of Physiological Regulation in Sleeping Mice (PRISM), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.
| |
Collapse
|
27
|
Bartoletti-Stella A, Gasparini L, Giacomini C, Corrado P, Terlizzi R, Giorgio E, Magini P, Seri M, Baruzzi A, Parchi P, Brusco A, Cortelli P, Capellari S. Messenger RNA processing is altered in autosomal dominant leukodystrophy. Hum Mol Genet 2017; 26:3868. [PMID: 28934398 PMCID: PMC5886215 DOI: 10.1093/hmg/ddx225] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Anna Bartoletti-Stella
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy
| | - Laura Gasparini
- Department of Neuroscience and Brain Techonologies, Istituto Italiano di Tecnologia, Genova 16163, Italy
| | - Caterina Giacomini
- Department of Neuroscience and Brain Techonologies, Istituto Italiano di Tecnologia, Genova 16163, Italy
| | - Patrizia Corrado
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy
| | - Rossana Terlizzi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy.,IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Elisa Giorgio
- Department of Medical Sciences, University of Torino, Torino 10126, Italy
| | - Pamela Magini
- Medical Genetics Unit, Department of Medical and Surgical Sciences, University of Bologna 40138, Italy
| | - Marco Seri
- Medical Genetics Unit, Department of Medical and Surgical Sciences, University of Bologna 40138, Italy
| | - Agostino Baruzzi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Piero Parchi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy.,IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Alfredo Brusco
- Department of Medical Sciences, University of Torino, Torino 10126, Italy.,Città della Salute e della Scienza, University Hospital, Medical Genetics Unit, Torino 10126, Italy
| | - Pietro Cortelli
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy.,IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Sabina Capellari
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy.,IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| |
Collapse
|
28
|
Mahajani S, Giacomini C, Marinaro F, De Pietri Tonelli D, Contestabile A, Gasparini L. Lamin B1 levels modulate differentiation into neurons during embryonic corticogenesis. Sci Rep 2017; 7:4897. [PMID: 28687747 PMCID: PMC5501862 DOI: 10.1038/s41598-017-05078-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Accepted: 05/24/2017] [Indexed: 01/10/2023] Open
Abstract
Lamin B1, a key component of the nuclear lamina, plays an important role in brain development. Ablation of endogenous Lamin B1 (Lmnb1) in the mouse strongly impairs embryonic brain development and corticogenesis. However, the mechanisms underlying these neurodevelopmental effects are unknown. Here, we report that Lamin B1 levels modulate the differentiation of murine neural stem cells (NSCs) into neurons and astroglial-like cells. In vitro, endogenous Lmnb1 depletion favors NSC differentiation into glial fibrillar acidic protein (GFAP)-immunoreactive cells over neurons, while overexpression of human Lamin B1 (LMNB1) increases the proportion of neurons. In Lmnb1-null embryos, neurogenesis is reduced, while in vivo Lmnb1 silencing in mouse embryonic brain by in utero electroporation of a specific Lmnb1 sh-RNA results in aberrant cortical positioning of neurons and increased expression of the astrocytic marker GFAP in the cortex of 7-day old pups. Together, these results indicate that finely tuned levels of Lamin B1 are required for NSC differentiation into neurons, proper expression of the astrocytic marker GFAP and corticogenesis.
Collapse
Affiliation(s)
- Sameehan Mahajani
- Dept. of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
- Universitaetsmedizin Goettingen, Waldweg 33, Goettingen, 37073, Germany
| | - Caterina Giacomini
- Dept. of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
- Division of Cancer Studies, King's College London, New Hunt's House, Guy's Campus, London, SE1 1UL, UK
| | - Federica Marinaro
- Dept. of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
| | | | - Andrea Contestabile
- Dept. of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
| | - Laura Gasparini
- Dept. of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy.
- Abbvie Deutschland GmbH & Co, Knollstr, Ludwigshafen, 67061, Germany.
| |
Collapse
|
29
|
Marafini M, Gasparini L, Mirabelli R, Pinci D, Patera V, Sciubba A, Spiriti E, Stoppa D, Traini G, Sarti A. MONDO: a neutron tracker for particle therapy secondary emission characterisation. Phys Med Biol 2017; 62:3299-3312. [PMID: 28350543 DOI: 10.1088/1361-6560/aa623a] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Tumour control is performed in particle therapy using particles and ions, whose high irradiation precision enhances the effectiveness of the treatment, while sparing the healthy tissue surrounding the target volume. Dose range monitoring devices using photons and charged particles produced by the beam interacting with the patient's body have already been proposed, but no attempt has been made yet to exploit the detection of the abundant neutron component. Since neutrons can release a significant dose far away from the tumour region, precise measurements of their flux, production energy and angle distributions are eagerly sought in order to improve the treatment planning system (TPS) software. It will thus be possible to predict not only the normal tissue toxicity in the target region, but also the risk of late complications in the whole body. The aforementioned issues underline the importance of an experimental effort devoted to the precise characterisation of neutron production, aimed at the measurement of their abundance, emission point and production energy. The technical challenges posed by a neutron detector aimed at high detection efficiency and good backtracking precision are addressed within the MONDO (monitor for neutron dose in hadrontherapy) project, whose main goal is to develop a tracking detector that can target fast and ultrafast neutrons. A full reconstruction of two consecutive elastic scattering interactions undergone by the neutrons inside the detector material will be used to measure their energy and direction. The preliminary results of an MC simulation performed using the FLUKA software are presented here, together with the DSiPM (digital SiPM) readout implementation. New detector readout implementations specifically tailored to the MONDO tracker are also discussed, and the neutron detection efficiency attainable with the proposed neutron tracking strategy are reported.
Collapse
Affiliation(s)
- M Marafini
- INFN Sezione di Roma, Rome, Italy. Museo Storico della Fisica e Centro Studi e Ricerche 'E. Fermi', Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Schierle GSK, Michel CH, Gasparini L. Advanced imaging of tau pathology in Alzheimer Disease: New perspectives from super resolution microscopy and label-free nanoscopy. Microsc Res Tech 2016; 79:677-83. [DOI: 10.1002/jemt.22698] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 05/19/2016] [Indexed: 01/20/2023]
Affiliation(s)
- Gabriele S. Kaminski Schierle
- Department of Chemical Engineering and Biotechnology; Pembroke Street, University of Cambridge; Cambridge CB2 3RA United Kingdom
| | - Claire H. Michel
- Department of Chemical Engineering and Biotechnology; Pembroke Street, University of Cambridge; Cambridge CB2 3RA United Kingdom
| | - Laura Gasparini
- Department of Neuroscience and Brain Technologies; Istituto Italiano di Tecnologia; Via Morego 30 Genova Italy
| |
Collapse
|
31
|
Barini E, Antico O, Zhao Y, Asta F, Tucci V, Catelani T, Marotta R, Xu H, Gasparini L. Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Mol Neurodegener 2016; 11:16. [PMID: 26858121 PMCID: PMC4746897 DOI: 10.1186/s13024-016-0082-7] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 02/01/2016] [Indexed: 11/10/2022] Open
Abstract
Background Alzheimer disease (AD) and other tauopathies develop cerebral intracellular inclusions of hyperphosphorylated tau. Epidemiological and experimental evidence suggests a clear link between type 2 diabetes mellitus and AD. In AD animal models, tau pathology is exacerbated by metabolic comorbidities, such as insulin resistance and diabetes. Within this context, anitidiabetic drugs, including the widely-prescribed insulin-sensitizing drug metformin, are currently being investigated for AD therapy. However, their efficacy for tauopathy in vivo has not been tested. Results Here, we report that in the P301S mutant human tau (P301S) transgenic mouse model of tauopathy, chronic administration of metformin exerts paradoxical effects on tau pathology. Despite reducing tau phosphorylation in the cortex and hippocampus via AMPK/mTOR and PP2A, metformin increases insoluble tau species (including tau oligomers) and the number of inclusions with β-sheet aggregates in the brain of P301S mice. In addition, metformin exacerbates hindlimb atrophy, increases P301S hyperactive behavior, induces tau cleavage by caspase 3 and disrupts synaptic structures. Conclusions These findings indicate that metformin pro-aggregation effects mitigate the potential benefits arising from its dephosphorylating action, possibly leading to an overall increase of the risk of tauopathy in elderly diabetic patients. Electronic supplementary material The online version of this article (doi:10.1186/s13024-016-0082-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Erica Barini
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy
| | - Odetta Antico
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy
| | - Yingjun Zhao
- Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, 361102, China.,Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA
| | - Francesco Asta
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy
| | - Valter Tucci
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy
| | - Tiziano Catelani
- Nanochemistry Department, Electron Microscopy Lab, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy
| | - Roberto Marotta
- Nanochemistry Department, Electron Microscopy Lab, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy
| | - Huaxi Xu
- Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, 361102, China.,Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA
| | - Laura Gasparini
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, Genoa, Italy. .,Present Address: AbbVie Deutschland GmbH &Co. KG, Knollstr., 67061, Ludwigshafen, Germany.
| |
Collapse
|
32
|
Giacomini C, Mahajani S, Ruffilli R, Marotta R, Gasparini L. Lamin B1 protein is required for dendrite development in primary mouse cortical neurons. Mol Biol Cell 2016; 27:35-47. [PMID: 26510501 PMCID: PMC4694760 DOI: 10.1091/mbc.e15-05-0307] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 10/07/2015] [Accepted: 10/23/2015] [Indexed: 01/15/2023] Open
Abstract
Lamin B1, a key component of the nuclear lamina, plays an important role in brain development and function. A duplication of the human lamin B1 (LMNB1) gene has been linked to adult-onset autosomal dominant leukodystrophy, and mouse and human loss-of-function mutations in lamin B1 are susceptibility factors for neural tube defects. In the mouse, experimental ablation of endogenous lamin B1 (Lmnb1) severely impairs embryonic corticogenesis. Here we report that in primary mouse cortical neurons, LMNB1 overexpression reduces axonal outgrowth, whereas deficiency of endogenous Lmnb1 results in aberrant dendritic development. In the absence of Lmnb1, both the length and complexity of dendrites are reduced, and their growth is unresponsive to KCl stimulation. This defective dendritic outgrowth stems from impaired ERK signaling. In Lmnb1-null neurons, ERK is correctly phosphorylated, but phospho-ERK fails to translocate to the nucleus, possibly due to delocalization of nuclear pore complexes (NPCs) at the nuclear envelope. Taken together, these data highlight a previously unrecognized role of lamin B1 in dendrite development of mouse cortical neurons through regulation of nuclear shuttling of specific signaling molecules and NPC distribution.
Collapse
Affiliation(s)
- Caterina Giacomini
- Molecular Neurodegeneration Lab, Neuroscience and Brain Technologies Department, 16163 Genoa, Italy
| | - Sameehan Mahajani
- Molecular Neurodegeneration Lab, Neuroscience and Brain Technologies Department, 16163 Genoa, Italy
| | - Roberta Ruffilli
- Electron Microscopy Lab, Nanochemistry Department, Istituto Italiano di Tecnologia, 16163 Genoa, Italy
| | - Roberto Marotta
- Electron Microscopy Lab, Nanochemistry Department, Istituto Italiano di Tecnologia, 16163 Genoa, Italy
| | - Laura Gasparini
- Molecular Neurodegeneration Lab, Neuroscience and Brain Technologies Department, 16163 Genoa, Italy
| |
Collapse
|
33
|
Chegaev K, Federico A, Marini E, Rolando B, Fruttero R, Morbin M, Rossi G, Fugnanesi V, Bastone A, Salmona M, Badiola NB, Gasparini L, Cocco S, Ripoli C, Grassi C, Gasco A. NO-donor thiacarbocyanines as multifunctional agents for Alzheimer's disease. Bioorg Med Chem 2015; 23:4688-4698. [PMID: 26078011 DOI: 10.1016/j.bmc.2015.05.050] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Revised: 05/26/2015] [Accepted: 05/29/2015] [Indexed: 12/31/2022]
Abstract
Some symmetrical and unsymmetrical thiacarbocyanines bearing NO-donor nitrooxy and furoxan moieties were synthesized and studied as candidate anti-Alzheimer's drugs. All products activated soluble guanylate cyclase (sGC) in a dose-dependent manner, depending on the presence in their structures of NO-donor groups. None displayed toxicity when tested at concentrations below 10 μM on human brain microvascular endothelial cells (hCMEC/D3). Some products were capable of inhibiting amyloid β-protein (Aβ) aggregation, with a potency in the low μM concentration range, and of inhibiting aggregation of human recombinant tau protein in amyloid fibrils when incubated with the protein at 1 μM concentration. Nitrooxy derivative 21 and furoxan derivative 22 were selected to investigate synaptic plasticity. Both products, tested at 2 μM concentration, counteracted the inhibition of long-term potentiation (LTP) induced by Aβ42 in hippocampal brain slices.
Collapse
Affiliation(s)
- Konstantin Chegaev
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
| | - Antonella Federico
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
| | - Elisabetta Marini
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
| | - Barbara Rolando
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
| | - Roberta Fruttero
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy.
| | - Michela Morbin
- Division of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
| | - Giacomina Rossi
- Division of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
| | - Valeria Fugnanesi
- Division of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
| | - Antonio Bastone
- Department of Molecular Biochemistry and Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano, Italy
| | - Mario Salmona
- Department of Molecular Biochemistry and Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano, Italy
| | - Nahuai B Badiola
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
| | - Laura Gasparini
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
| | - Sara Cocco
- Institute of Human Physiology, UniversitàCattolica, Roma, Italy
| | - Cristian Ripoli
- Institute of Human Physiology, UniversitàCattolica, Roma, Italy
| | - Claudio Grassi
- Institute of Human Physiology, UniversitàCattolica, Roma, Italy
| | - Alberto Gasco
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
| |
Collapse
|
34
|
Giorgio E, Robyr D, Spielmann M, Ferrero E, Di Gregorio E, Imperiale D, Vaula G, Stamoulis G, Santoni F, Atzori C, Gasparini L, Ferrera D, Canale C, Guipponi M, Pennacchio LA, Antonarakis SE, Brussino A, Brusco A. A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD). Hum Mol Genet 2015; 24:3143-54. [PMID: 25701871 PMCID: PMC4424952 DOI: 10.1093/hmg/ddv065] [Citation(s) in RCA: 97] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 02/13/2015] [Indexed: 01/23/2023] Open
Abstract
Chromosomal rearrangements with duplication of the lamin B1 (LMNB1) gene underlie autosomal dominant adult-onset demyelinating leukodystrophy (ADLD), a rare neurological disorder in which overexpression of LMNB1 causes progressive central nervous system demyelination. However, we previously reported an ADLD family (ADLD-1-TO) without evidence of duplication or other mutation in LMNB1 despite linkage to the LMNB1 locus and lamin B1 overexpression. By custom array-CGH, we further investigated this family and report here that patients carry a large (∼660 kb) heterozygous deletion that begins 66 kb upstream of the LMNB1 promoter. Lamin B1 overexpression was confirmed in further ADLD-1-TO tissues and in a postmortem brain sample, where lamin B1 was increased in the frontal lobe. Through parallel studies, we investigated both loss of genetic material and chromosomal rearrangement as possible causes of LMNB1 overexpression, and found that ADLD-1-TO plausibly results from an enhancer adoption mechanism. The deletion eliminates a genome topological domain boundary, allowing normally forbidden interactions between at least three forebrain-directed enhancers and the LMNB1 promoter, in line with the observed mainly cerebral localization of lamin B1 overexpression and myelin degeneration. This second route to LMNB1 overexpression and ADLD is a new example of the relevance of regulatory landscape modifications in determining Mendelian phenotypes.
Collapse
Affiliation(s)
- Elisa Giorgio
- Department of Medical Sciences, University of Torino, via Santena, 19, Torino 10126, Italy
| | - Daniel Robyr
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva 1211, Switzerland
| | - Malte Spielmann
- Max Planck Institute for Molecular Genetics, Ihnestr. 63-73, Berlin 14195, Germany
| | - Enza Ferrero
- Department of Medical Sciences, University of Torino, via Santena, 19, Torino 10126, Italy
| | - Eleonora Di Gregorio
- Department of Medical Sciences, University of Torino, via Santena, 19, Torino 10126, Italy Medical Genetics Unit and
| | - Daniele Imperiale
- Centro Regionale Malattie Da Prioni - Domp (ASLTO2), Torino 10144, Italy
| | - Giovanna Vaula
- Department of Neurology, Città della Salute e della Scienza University Hospital, Torino 10126, Italy
| | - Georgios Stamoulis
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva 1211, Switzerland
| | - Federico Santoni
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva 1211, Switzerland
| | - Cristiana Atzori
- Centro Regionale Malattie Da Prioni - Domp (ASLTO2), Torino 10144, Italy
| | | | | | - Claudio Canale
- Department of Nanophysics, Istituto Italiano di Tecnologia, Genoa 16163, Italy and
| | - Michel Guipponi
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva 1211, Switzerland
| | - Len A Pennacchio
- Genomics Division, Lawrence Berkeley National Laboratory, MS 84-171, Berkeley, CA 9472, USA
| | - Stylianos E Antonarakis
- Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva 1211, Switzerland
| | - Alessandro Brussino
- Department of Medical Sciences, University of Torino, via Santena, 19, Torino 10126, Italy
| | - Alfredo Brusco
- Department of Medical Sciences, University of Torino, via Santena, 19, Torino 10126, Italy Medical Genetics Unit and
| |
Collapse
|
35
|
Bartoletti-Stella A, Gasparini L, Giacomini C, Corrado P, Terlizzi R, Giorgio E, Magini P, Seri M, Baruzzi A, Parchi P, Brusco A, Cortelli P, Capellari S. Messenger RNA processing is altered in autosomal dominant leukodystrophy. Hum Mol Genet 2015; 24:2746-56. [PMID: 25637521 PMCID: PMC4406291 DOI: 10.1093/hmg/ddv034] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Accepted: 01/27/2015] [Indexed: 02/06/2023] Open
Abstract
Adult-onset autosomal dominant leukodystrophy (ADLD) is a slowly progressive neurological disorder characterized by autonomic dysfunction, followed by cerebellar and pyramidal features. ADLD is caused by duplication of the lamin B1 gene (LMNB1), which leads to its increased expression. The molecular pathways involved in the disease are still poorly understood. Hence, we analyzed global gene expression in fibroblasts and whole blood of LMNB1 duplication carriers and used Gene Set Enrichment Analysis to explore their gene signatures. We found that LMNB1 duplication is associated with dysregulation of genes involved in the immune system, neuronal and skeletal development. Genes with an altered transcriptional profile clustered in specific genomic regions. Among the dysregulated genes, we further studied the role of RAVER2, which we found to be overexpressed at mRNA and protein level. RAVER2 encodes a putative trans regulator of the splicing repressor polypyrimidine tract binding protein (PTB) and is likely implicated in alternative splicing regulation. Functional studies demonstrated an abnormal splicing pattern of several PTB-target genes and of the myelin protein gene PLP1, previously demonstrated to be involved in ADLD. Mutant mice with different lamin B1 expression levels confirmed that Raver2 expression is dependent on lamin B1 in neural tissue and determines an altered splicing pattern of PTB-target genes and Plp1. Overall our results demonstrate that deregulation of lamin B1 expression induces modified splicing of several genes, likely driven by raver-2 overexpression, and suggest that an alteration of mRNA processing could be a pathogenic mechanism in ADLD.
Collapse
Affiliation(s)
- Anna Bartoletti-Stella
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy
| | - Laura Gasparini
- Department of Neuroscience and Brain Techonologies, Istituto Italiano di Tecnologia, Genova 16163, Italy
| | - Caterina Giacomini
- Department of Neuroscience and Brain Techonologies, Istituto Italiano di Tecnologia, Genova 16163, Italy
| | - Patrizia Corrado
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy
| | - Rossana Terlizzi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy, IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Elisa Giorgio
- Department of Medical Sciences, University of Torino, Torino 10126, Italy
| | - Pamela Magini
- Medical Genetics Unit, Department of Medical and Surgical Sciences, University of Bologna 40138, Italy and
| | - Marco Seri
- Medical Genetics Unit, Department of Medical and Surgical Sciences, University of Bologna 40138, Italy and
| | - Agostino Baruzzi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Piero Parchi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy, IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Alfredo Brusco
- Department of Medical Sciences, University of Torino, Torino 10126, Italy, Città della Salute e della Scienza, University Hospital, Medical Genetics Unit, Torino 10126, Italy
| | - Pietro Cortelli
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy, IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy
| | - Sabina Capellari
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna 40123, Italy, IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Ospedale Bellaria, Bologna 40139, Italy,
| |
Collapse
|
36
|
Ferrera D, Mazzaro N, Canale C, Gasparini L. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage. Neurobiol Aging 2014; 35:2444-2457. [DOI: 10.1016/j.neurobiolaging.2014.05.023] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Revised: 05/12/2014] [Accepted: 05/22/2014] [Indexed: 10/25/2022]
|
37
|
Ferrera D, Canale C, Marotta R, Mazzaro N, Gritti M, Mazzanti M, Capellari S, Cortelli P, Gasparini L. Lamin B1 overexpression increases nuclear rigidity in autosomal dominant leukodystrophy fibroblasts. FASEB J 2014; 28:3906-18. [PMID: 24858279 PMCID: PMC4139899 DOI: 10.1096/fj.13-247635] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 05/12/2014] [Indexed: 12/22/2022]
Abstract
The architecture and structural mechanics of the cell nucleus are defined by the nuclear lamina, which is formed by A- and B-type lamins. Recently, gene duplication and protein overexpression of lamin B1 (LB1) have been reported in pedigrees with autosomal dominant leukodystrophy (ADLD). However, how the overexpression of LB1 affects nuclear mechanics and function and how it may result in pathology remain unexplored. Here, we report that in primary human skin fibroblasts derived from ADLD patients, LB1, but not other lamins, is overexpressed at the nuclear lamina and specifically enhances nuclear stiffness. Transient transfection of LB1 in HEK293 and neuronal N2a cells mimics the mechanical phenotype of ADLD nuclei. Notably, in ADLD fibroblasts, reducing LB1 protein levels by shRNA knockdown restores elasticity values to those indistinguishable from control fibroblasts. Moreover, isolated nuclei from ADLD fibroblasts display a reduced nuclear ion channel open probability on voltage-step application, suggesting that biophysical changes induced by LB1 overexpression may alter nuclear signaling cascades in somatic cells. Overall, the overexpression of LB1 in ADLD cells alters nuclear mechanics and is linked to changes in nuclear signaling, which could help explain the pathogenesis of this disease.
Collapse
Affiliation(s)
| | | | - Roberto Marotta
- Department of Nanochemistry, Istituto Italiano di Tecnologia, Genoa, Italy
| | | | - Marta Gritti
- Department of Biosciences, University of Milano, Milan, Italy
| | | | - Sabina Capellari
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Clinica Neurologica, Ospedale Bellaria, Bologna, Italy; and Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Pietro Cortelli
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Clinica Neurologica, Ospedale Bellaria, Bologna, Italy; and Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | | |
Collapse
|
38
|
Averaimo S, Gritti M, Barini E, Gasparini L, Mazzanti M. CLIC1 functional expression is required for cAMP-induced neurite elongation in post-natal mouse retinal ganglion cells. J Neurochem 2014; 131:444-56. [PMID: 25060644 DOI: 10.1111/jnc.12832] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2014] [Revised: 07/14/2014] [Accepted: 07/21/2014] [Indexed: 01/10/2023]
Abstract
During neuronal differentiation, axonal elongation is regulated by both external and intrinsic stimuli, including neurotropic factors, cytoskeleton dynamics, second messengers such as cyclic adenosine monophosphate (cAMP), and neuronal excitability. Chloride intracellular channel 1 (CLIC1) is a cytoplasmic hydrophilic protein that, upon stimulation, dimerizes and translocates to the plasma membrane, where it contributes to increase the membrane chloride conductance. Here, we investigated the expression of CLIC1 in primary hippocampal neurons and retinal ganglion cells (RGCs) and examined how the functional expression of CLIC1 specifically modulates neurite outgrowth of neonatal murine RGCs. Using a combination of electrophysiology and immunohistochemistry, we found that CLIC1 is expressed in hippocampal neurons and RGCs and that the chloride current mediated by CLIC1 is required for maintaining growth cone morphology and sustaining cAMP-stimulated neurite elongation in dissociated immunopurified RGCs. In cultured RGCs, inhibition of CLIC1 ionic current through the pharmacological blocker IAA94 or a specific anti-CLIC1 antibody directed against its extracellular domain prevents the neurite outgrowth induced by cAMP. CLIC1-mediated chloride current, which results from an increased open probability of the channel, is detected only when cAMP is elevated. Inhibition of protein kinase A prevents such current. These results indicate that CLIC1 functional expression is regulated by cAMP via protein kinase A and is required for neurite outgrowth modulation during neuronal differentiation. Using a combination of electrophysiology and immunohistochemistry, we found that the chloride intracellular channel 1 (CLIC1) protein modulates the speed of neurite growth. The chloride current mediated by CLIC1 is essential for maintaining growth cone morphology and is required for sustaining cAMP-stimulated neurite elongation in dissociated immunopurified neurons. The presence of either the CLIC1 current blocker IAA94 or the anti-CLIC1 antibody inhibits neurite growth of Retina Ganglion Cells cultured in the presence of 10 micromolar forskolin for 24 h.
Collapse
|
39
|
Tucci V, Kleefstra T, Hardy A, Heise I, Maggi S, Willemsen MH, Hilton H, Esapa C, Simon M, Buenavista MT, McGuffin LJ, Vizor L, Dodero L, Tsaftaris S, Romero R, Nillesen WN, Vissers LELM, Kempers MJ, Vulto-van Silfhout AT, Iqbal Z, Orlando M, Maccione A, Lassi G, Farisello P, Contestabile A, Tinarelli F, Nieus T, Raimondi A, Greco B, Cantatore D, Gasparini L, Berdondini L, Bifone A, Gozzi A, Wells S, Nolan PM. Dominant β-catenin mutations cause intellectual disability with recognizable syndromic features. J Clin Invest 2014; 124:1468-82. [PMID: 24614104 DOI: 10.1172/jci70372] [Citation(s) in RCA: 98] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2013] [Accepted: 01/09/2014] [Indexed: 12/18/2022] Open
Abstract
The recent identification of multiple dominant mutations in the gene encoding β-catenin in both humans and mice has enabled exploration of the molecular and cellular basis of β-catenin function in cognitive impairment. In humans, β-catenin mutations that cause a spectrum of neurodevelopmental disorders have been identified. We identified de novo β-catenin mutations in patients with intellectual disability, carefully characterized their phenotypes, and were able to define a recognizable intellectual disability syndrome. In parallel, characterization of a chemically mutagenized mouse line that displays features similar to those of human patients with β-catenin mutations enabled us to investigate the consequences of β-catenin dysfunction through development and into adulthood. The mouse mutant, designated batface (Bfc), carries a Thr653Lys substitution in the C-terminal armadillo repeat of β-catenin and displayed a reduced affinity for membrane-associated cadherins. In association with this decreased cadherin interaction, we found that the mutation results in decreased intrahemispheric connections, with deficits in dendritic branching, long-term potentiation, and cognitive function. Our study provides in vivo evidence that dominant mutations in β-catenin underlie losses in its adhesion-related functions, which leads to severe consequences, including intellectual disability, childhood hypotonia, progressive spasticity of lower limbs, and abnormal craniofacial features in adults.
Collapse
|
40
|
Colombi I, Mahajani S, Frega M, Gasparini L, Chiappalone M. Effects of antiepileptic drugs on hippocampal neurons coupled to micro-electrode arrays. Front Neuroeng 2013; 6:10. [PMID: 24312049 PMCID: PMC3832899 DOI: 10.3389/fneng.2013.00010] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Accepted: 10/21/2013] [Indexed: 11/13/2022]
Abstract
Hippocampal networks exhibit spontaneous electrophysiological activity that can be modulated by pharmacological manipulation and can be monitored over time using Micro-Electrode Arrays (MEAs), devices composed by a glass substrate and metal electrodes. The typical mode of activity of these dissociated cultures is the network-wide bursting pattern, which, if properly chemically modulated, can recall the ictal events of the epileptic phenotypes and is well-suited to study the effects of antiepileptic compounds. In this paper, we analyzed the changes induced by Carbamazepine (CBZ) and Valproate (VPA) on mature networks of hippocampal neurons in “control” condition (i.e., in the culturing medium) and upon treatment with the pro-convulsant bicuculline (BIC). We found that, in both control and BIC—treated networks, high doses (100 μM–1 mM) of CBZ almost completely suppressed the spiking and bursting activity of hippocampal neurons. On the contrary, VPA never completely abolish the electrophysiological activity in both experimental designs. Interestingly, VPA cultures pre-treated with BIC showed dual effects. In fact, in some cultures, at low VPA concentrations (100 nM–1 μM), we observed decreased firing/bursting levels, which returned to values comparable to BIC-evoked activity at high VPA concentrations (100 μM–1 mM). In other cultures, VPA reduced BIC-evoked activity in a concentration-independent manner. In conclusion, our study demonstrates that MEA-coupled hippocampal networks are responsive to chemical manipulations and, upon proper pharmacological modulation, might provide model systems to detect acute pharmacological effects of antiepileptic drugs.
Collapse
Affiliation(s)
- Ilaria Colombi
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia Genova, Italy
| | | | | | | | | |
Collapse
|
41
|
Mazzaro N, Barini E, Goedert M, Spillantini MG, Medini P, Gasparini L. Tauopathy-induced retinal dysfunction in the P301S mutant human tau transgenic mouse. Mol Neurodegener 2013. [PMCID: PMC3850658 DOI: 10.1186/1750-1326-8-s1-p57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Barini E, Mazzaro N, Spillantini MG, Goedert M, Medini P, Gasparini L. P1–046: Alterations of neurotrophin signaling in the retina of the P301S mutant human tau transgenic mouse. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | - Michel Goedert
- MRC Laboratory of Molecular Biology Cambridge United Kingdom
| | | | | |
Collapse
|
43
|
Mazzaro N, Barini E, Spillantini MG, Goedert M, Medini P, Gasparini L. P1–045: Neurotrophin signaling is altered in the retina of the P301S mutant human tau transgenic mouse. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | - Michel Goedert
- MRC Laboratory of Molecular Biology Cambridge United Kingdom
| | | | | |
Collapse
|
44
|
Columbaro M, Mattioli E, Maraldi NM, Ortolani M, Gasparini L, D'Apice MR, Postorivo D, Nardone AM, Avnet S, Cortelli P, Liguori R, Lattanzi G. Oct-1 recruitment to the nuclear envelope in adult-onset autosomal dominant leukodystrophy. Biochim Biophys Acta 2013; 1832:411-20. [PMID: 23261988 DOI: 10.1016/j.bbadis.2012.12.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Revised: 11/16/2012] [Accepted: 12/10/2012] [Indexed: 01/29/2023]
Abstract
Adult-onset autosomal dominant leukodystrophy (ADLD) is a slowly progressive neurological disorder characterised by pyramidal, cerebellar, and autonomic disturbances. Duplication of the LMNB1 gene is the genetic cause of ADLD, yet the pathogenetic mechanism is not defined. In this study, we analysed cells and muscle tissue from three patients affected by ADLD, carrying an extra copy of the LMNB1 gene. Lamin B1 levels were dramatically increased in ADLD nuclei, both in skin fibroblasts and skeletal muscle fibres. Since lamin B1 is known to bind Oct-1, a transcription factor involved in the oxidative stress pathway, we investigated Oct-1 fate in ADLD. Oct-1 recruitment to the nuclear periphery was increased in ADLD cells, while nucleoplasmic localisation of the transcription factor under oxidative stress conditions was reduced. Importantly, lamin B1 degradation occurring in some, but not all ADLD cell lines, slowed down lamin B1 and Oct-1 accumulation. In skeletal muscle, focal disorganisation of sarcomeres was observed, while IIB-myosin heavy chain, an Oct-1 target gene, was under-expressed and rod-containing fibres were formed. These data show that a high degree of regulation of lamin B1 expression is implicated in the different clinical phenotypes observed in ADLD and show that altered Oct-1 nuclear localisation contributes to the disease phenotype.
Collapse
|
45
|
Contestabile A, Greco B, Ghezzi D, Tucci V, Benfenati F, Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest 2012. [PMID: 23202733 DOI: 10.1172/jci64650] [Citation(s) in RCA: 119] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Down syndrome (DS) patients exhibit abnormalities of hippocampal-dependent explicit memory, a feature that is replicated in relevant mouse models of the disease. Adult hippocampal neurogenesis, which is impaired in DS and other neuropsychiatric diseases, plays a key role in hippocampal circuit plasticity and has been implicated in learning and memory. However, it remains unknown whether increasing adult neurogenesis improves hippocampal plasticity and behavioral performance in the multifactorial context of DS. We report that, in the Ts65Dn mouse model of DS, chronic administration of lithium, a clinically used mood stabilizer, promoted the proliferation of neuronal precursor cells through the pharmacological activation of the Wnt/β-catenin pathway and restored adult neurogenesis in the hippocampal dentate gyrus (DG) to physiological levels. The restoration of adult neurogenesis completely rescued the synaptic plasticity of newborn neurons in the DG and led to the full recovery of behavioral performance in fear conditioning, object location, and novel object recognition tests. These findings indicate that reestablishing a functional population of hippocampal newborn neurons in adult DS mice rescues hippocampal plasticity and memory and implicate adult neurogenesis as a promising therapeutic target to alleviate cognitive deficits in DS patients.
Collapse
Affiliation(s)
- Andrea Contestabile
- Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy.
| | | | | | | | | | | |
Collapse
|
46
|
Ferrera D, Canale C, Benfenati F, Gasparini L. P2‐328: Microglia discriminates β‐amyloid aggregated species and acquire different activation states. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Scattoni ML, Gasparini L, Alleva E, Goedert M, Calamandrei G, Spillantini MG. Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res 2009; 208:250-7. [PMID: 20004218 DOI: 10.1016/j.bbr.2009.12.002] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2009] [Revised: 12/01/2009] [Accepted: 12/02/2009] [Indexed: 10/20/2022]
Abstract
The present study aimed at characterizing the early behavioural changes preceding the onset of disease in a transgenic mouse model of tauopathy. Mice transgenic for human P301S tau protein exhibit many characteristics of human tauopathies, including neurodegeneration, the formation of neuronal tau inclusions in the brain and the development of a pronounced motor phenotype by 5 months of age. In this study we analyzed the ultrasonic vocalization pattern in the first week of life and the response to nest-related olfactory stimuli on postnatal day 10 in both homozygous and heterozygous transgenic mice in comparison with the behavioural responses of C57BL/6J pups. Expression of human tau in the brain and spinal cord was evaluated by Western blot analysis. Homozygous P301S tau transgenic and C57BL/6J mice were also assessed for motor coordination in the Rotarod apparatus at 1, 2, 3 and 4 months of age, and spatial learning and spontaneous behaviour were evaluated at 2 months in the Morris water-maze and the open-field test. Results showed that P301S pups emitted more ultrasounds than C57BL/6J pups when separated from the mother. Two-month-old P301S mice displayed a hyperactive profile, as shown by increased swimming speed, enhanced locomotion and exploration of a novel object in the open field. However, the spatial task acquisition was unaltered. Decline of motor coordination capacities was evident only by the third month of age in the rotarod test. Behavioural abnormalities can be detected well before occurrence of neurodegeneration in this transgenic strain, thus representing precocious markers of pathology.
Collapse
Affiliation(s)
- Maria Luisa Scattoni
- Neurotoxicology and Neuroendocrinology Section, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
48
|
Ferrera D, Canale C, Benfenati F, Gasparini L. P1‐167: Effects of beta‐amyloid oligomers on neuronal viability and microglial activation. Alzheimers Dement 2009. [DOI: 10.1016/j.jalz.2009.04.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Denise Ferrera
- Dept. of Neuroscience and Brain TechnologiesThe Italian Institute of TechnologyGENOVAItaly
| | - Claudio Canale
- Nanobiotechnology PlatformThe Italian Institute of TechnologyGENOVAItaly
| | - Fabio Benfenati
- Dept. of Neuroscience and Brain TechnologiesThe Italian Institute of TechnologyGENOVAItaly
| | - Laura Gasparini
- Dept. of Neuroscience and Brain TechnologiesThe Italian Institute of TechnologyGENOVAItaly
| |
Collapse
|
49
|
Gasparini L, Crowther RA, Martin KR, Berg N, Coleman M, Goedert M, Spillantini MG. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol Aging 2009; 32:419-33. [PMID: 19356824 DOI: 10.1016/j.neurobiolaging.2009.03.002] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2008] [Revised: 02/09/2009] [Accepted: 03/03/2009] [Indexed: 12/17/2022]
Abstract
Tau inclusions play a key role in the pathogenesis of tauopathies. Altered tau levels have been detected in retina and optic nerve of patients with glaucoma, suggesting the possibility of shared pathogenic mechanisms with tauopathies. Here we report that hyperphosphorylated transgenic tau accumulates in the nerve fibre layer and, from 2 months of age, aggregates into filamentous inclusions in retinal ganglion cells of human P301S tau transgenic mice. Axonopathy and accumulation of hyperphosphorylated tau in the nerve fibre layer preceded inclusion formation. Hyperphosphorylated tau and tau inclusions were also detected in cultured retinal explants from 5-month-old transgenic mice. Axonal outgrowth was similar in transgenic and wild-type retinal explants under basal conditions. However, when exposed to growth-promoting stimuli, axon elongation was enhanced in explants from wild-type but not transgenic mice, indicating that the presence of abnormal tau can impair stimulated axonal outgrowth. These findings suggest that the retina is a good model system for investigating tau-driven neurodegeneration and for assessing potential pharmacological modifiers for tauopathies.
Collapse
Affiliation(s)
- Laura Gasparini
- Cambridge Centre for Brain Repair, The University of Cambridge, Robinson Way, Forvie site, Cambridge CB2 0PY, UK.
| | | | | | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- Laura Gasparini
- Department of Neuroscience and Brain Technologies, The Italian Institute of Technology, 16163 Genova, Italy
| | | |
Collapse
|